Monograph
M03BA03 - Methocarbamol |
Propably not porphyrinogenic |
PNP |
Rationale
Methocarbamol does not show potential for interaction with CYP enzymes, and no porphyrinogenic effects have been identified.
Chemical description
Carbamatic acid ester
Therapeutic characteristics
Methocarbamol is a centrally acting muscle relaxant used in the treatment of musculoskeletal pain. It is administered orally or intravenously, and has a half-life of about 2 hours (SPC).
Metabolism and pharmacokinetics
Methocarbamol is metabolised in the liver, but data on the involvement of CYP enzymes are lacking (SPC, DrugBank). Methocarbamol did not show any potential for significant interactions with CYP3A4, CYP2C8, CYP2B6 or CYP2D6 in an in vitro study (Moody 2018).
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Norway
Poland
Luxembourg© NAPOS 2024